Literature DB >> 2014863

Targeted HIV screening at a Los Angeles prenatal/family planning health center.

L J Fehrs1, D Hill, P R Kerndt, T P Rose, C Henneman.   

Abstract

In 1988, the Los Angeles County Health Department conducted a blinded human immunodeficiency virus (HIV) seroprevalence study at a public prenatal (PN) and family planning (FP) center serving mostly Hispanic women in order to determine seroprevalence and to evaluate the center's targeted HIV screening program. Four women (0.13 percent) tested positive (3/1801 PN and 1/1167 FP). Three reported no risk factors; one reported a history of syphilis since 1978. Voluntary HIV testing was selectively offered to women who reported risk factors for HIV infection. Only 14 percent (96/685) of clients offered testing chose to do it: 28 percent (14/50) of clients classified as being at highest risk of infection, and 27 percent (16/59) of women who judged themselves to have some chance of being exposed to HIV. None of the four women who tested positive by blinded testing chose testing. While few women at this center were infected with HIV, higher risk women were not persuaded to be tested through a targeted screening program. Blinded HIV seroprevalence studies provide a tool for both tracking infection in a population and evaluating screening programs.

Entities:  

Mesh:

Year:  1991        PMID: 2014863      PMCID: PMC1405093          DOI: 10.2105/ajph.81.5.619

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  14 in total

1.  Hospital policy, practice re HIV testing for pregnant women and newborns.

Authors:  R M Schwartz; E C Maynard
Journal:  Am J Public Health       Date:  1990-10       Impact factor: 9.308

2.  Routine hepatitis screening in adolescent pregnancies: is it cost effective?

Authors:  A M Wetzel; D S Kirz
Journal:  Am J Obstet Gynecol       Date:  1987-01       Impact factor: 8.661

3.  Failure of voluntary testing for human immunodeficiency virus to identify infected parturient women in a high-risk population.

Authors:  K Krasinski; W Borkowsky; D Bebenroth; T Moore
Journal:  N Engl J Med       Date:  1988-01-21       Impact factor: 91.245

4.  HIV seroprevalence in newborns in New York State.

Authors:  L F Novick; D Berns; R Stricof; R Stevens; K Pass; J Wethers
Journal:  JAMA       Date:  1989 Mar 24-31       Impact factor: 56.272

5.  The case for wider use of testing for HIV infection.

Authors:  F S Rhame; D G Maki
Journal:  N Engl J Med       Date:  1989-05-11       Impact factor: 91.245

6.  HIV seroprevalence rate at the Boston City Hospital.

Authors:  S P Donegan; K C Edelin; D E Craven
Journal:  N Engl J Med       Date:  1988-09-08       Impact factor: 91.245

7.  [The rectus femoris muscle--the beginning tendon, its functional significance].

Authors:  M Doskocil; M Med; T Vimmer
Journal:  Acta Chir Orthop Traumatol Cech       Date:  1987-04       Impact factor: 0.531

8.  Serosurvey of human immunodeficiency virus infection in parturients. Implications for human immunodeficiency virus testing programs of pregnant women.

Authors:  S Landesman; H Minkoff; S Holman; S McCalla; O Sijin
Journal:  JAMA       Date:  1987-11-20       Impact factor: 56.272

9.  The family of HIV seroprevalence surveys: objectives, methods, and uses of sentinel surveillance for HIV in the United States.

Authors:  M Pappaioanou; T J Dondero; L R Petersen; I M Onorato; C D Sanchez; J W Curran
Journal:  Public Health Rep       Date:  1990 Mar-Apr       Impact factor: 2.792

10.  Prevalence of hepatitis B virus infection in pregnant women in the Montreal area.

Authors:  G Delage; S Montplaisir; S Rémy-Prince; E Pierri
Journal:  CMAJ       Date:  1986-04-15       Impact factor: 8.262

View more
  9 in total

1.  Periodic health examination, 1992 update: 3. HIV antibody screening. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  CMAJ       Date:  1992-09-15       Impact factor: 8.262

2.  Prenatal HIV testing in Ontario: knowledge, attitudes and practices of prenatal care providers in a province with low testing rates.

Authors:  Dale Guenter; June Carroll; Janusz Kaczorowski; John Sellors
Journal:  Can J Public Health       Date:  2003 Mar-Apr

3.  Do physicians discuss HIV testing during prenatal care?

Authors:  G Ogilvie; S Adsett; G Macdonald
Journal:  Can Fam Physician       Date:  1997-08       Impact factor: 3.275

4.  Prenatal HIV tests. Routine testing or informed choice?

Authors:  Dale Guenter; Janusz Kaczorowski; June Carroll; John Sellors
Journal:  Can Fam Physician       Date:  2003-10       Impact factor: 3.275

5.  Evidence-based guidelines for universal counselling and offering of HIV testing in pregnancy in Canada.

Authors:  L Samson; S King
Journal:  CMAJ       Date:  1998-06-02       Impact factor: 8.262

6.  A state program for postpartum HIV counseling and testing.

Authors:  S Holman; M D Sorin; J Crossette; M L LaChance-McCullough
Journal:  Public Health Rep       Date:  1994 Jul-Aug       Impact factor: 2.792

7.  Prevalence of HIV infection among inpatients and outpatients in Department of Veterans Affairs health care systems: implications for screening programs for HIV.

Authors:  Douglas K Owens; Vandana Sundaram; Laura C Lazzeroni; Lena R Douglass; Gillian D Sanders; Kathie Taylor; Ronald VanGroningen; Vera M Shadle; Valerie C McWhorter; Teodora Agoncillo; Noreen Haren; Jill Nyland; Patricia Tempio; Walid Khayr; Dennis J Dietzen; Peter Jensen; Michael S Simberkoff; Samuel A Bozzette; Mark Holodniy
Journal:  Am J Public Health       Date:  2007-10-30       Impact factor: 9.308

8.  HIV infection among women undergoing abortion in Montreal.

Authors:  R S Remis; E L Eason; R W Palmer; M Najjar; P Leclerc; F Lebel; M Fauvel
Journal:  CMAJ       Date:  1995-11-01       Impact factor: 8.262

9.  Opt-out bloodborne virus screening: a cross-sectional observational study in an acute medical unit.

Authors:  Niamh Allen; Collette Faherty; Andre Davies; Anne Lyons; Margarent Scarry; Mary Bohan Keane; Nicola Boyle; Sarah O'Connell; Eithne McCarthy; Deirbhile Keady; Colm Bergin; John Lee; Catherine Fleming; David Gallagher; Helen Tuite
Journal:  BMJ Open       Date:  2019-07-16       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.